00:34 , Jun 30, 2017 |  BC Extra  |  Preclinical News

Hormone tied to treating preeclampsia

In a paper published in Science, researchers at Singapore's Agency for Science Technology and Research (A*STAR) show lack of a hormone normally secreted by the placenta in pregnant mice led to preeclampsia symptoms, and treatment...
01:34 , Apr 1, 2015 |  BC Extra  |  Financial News

Thrasos raises $21M in series D

Thrasos Therapeutics Inc. (Montreal, Quebec) raised $21 million in a series D round led by new investor BDC Capital and existing investor SR One. Current investors Advanced Technology Ventures; Fonds de solidarite FTQ; Lumira Capital;...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Milestone Pharmaceuticals board of directors update

Milestone Pharmaceuticals Inc., Montreal, Quebec   Business: Cardiovascular   Appointed: Ela Borenstein, partner at BDC Health Venture Fund; Dominic Jaikaran, principal at BDC Health Venture Fund; Eric Linsley, managing partner at Pappas Ventures; and Scott Weiner, senior...
07:00 , Jun 20, 2011 |  BioCentury  |  Finance

Making the Milestone

Making the Milestone The venture arm of the Business Development Bank of Canada helped lead a C$13 million ($13.3 million) series A round last week in cardiovascular play Milestone Pharmaceuticals Inc. The financing is intended to...
08:00 , Nov 22, 1999 |  BC Week In Review  |  Clinical News

CroTAb rattlesnake antivenom regulatory update

PTI said that the FDA has requested supplemental data to validate the manufacturing process for CroTAb to support the company's ELA for the product, which is under review. PTI said that while the issues do...
07:00 , Oct 25, 1999 |  BioCentury  |  Strategy

North American Vaccine: 4th strike

When its Certiva diphtheria, tetanus and acellular pertussis (DTaP) vaccine received FDA approval last year, North American Vaccine Inc. hoped that its marketing deal with Abbott Laboratories would allow the product to compete with the...
07:00 , Oct 18, 1999 |  BC Week In Review  |  Clinical News

DigiTAb polyclonal antibody regulatory update

The FDA accepted for filing PTI's PLA/ELA for its DigiTAb to treat digoxin (digitalis) toxicity. The acceptance triggered a $250,000 milestone payment from U.S. marketing partner Altana Inc. (Melville, N.Y.). Protherics PLC (LSE:PTI), Macclesfield,...
07:00 , Aug 16, 1999 |  BC Week In Review  |  Clinical News

DigiTAb polyclonal antibody regulatory update

TAB submitted a PLA and an Establishment License Application (ELA) to the FDA for DigiTAb to treat digoxin (digitalis) toxicity. Altana Inc. (Melville, N.Y.) has U.S. marketing rights to the product. Therapeutic Antibodies Inc....
08:00 , Mar 1, 1999 |  BioCentury  |  Finance

A dry spell is broken

While it had begun to look as if not a single IPO or follow-on would get done this quarter, the spell was finally broken on Friday as Invitrogen (IVGN) raised $45 million in its IPO,...
08:00 , Feb 8, 1999 |  BioCentury  |  Finance

Placebo pills?

The number of shareholder rights plans - a.k.a. poison pills - implemented for biotech companies might lead an outsider to believe that the industry is fraught with hostile takeover bids. Last week Triangle (VIRS), a...